Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Part of paid clinical trials in Duarte, California.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT00253630
- Phase
- PHASE2
- Status
- Completed
Conditions
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Nodal Marginal Zone Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Laboratory Biomarker Analysis — OTHERCorrelative studies
- Vorinostat — DRUGGiven PO
Study Details
This phase II trial is studying how well vorinostat works in treating patients with relapsed or refractory indolent non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Key Dates
- Start date
- Sep 30, 2005
- Status verified
- Feb 2018
- Primary completion
- May 31, 2016
- Completion
- May 31, 2016
Study Design
- Enrollment
- 37 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (vorinostat)Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Response Rate [ Time Frame: Up to 3 years ]
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | - |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | - |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | - |
| City of Hope South Pasadena | South Pasadena | California | 91030 | - |
| University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania | 15232 | - |
Find similar trials in Duarte, CA
By research site
Related Studies
- Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell LymphomaPHASE2 · Recruiting · City of Hope Medical Center · Duarte, California
- Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin LymphomaPHASE1 · Recruiting · City of Hope Medical Center · Duarte, California
- Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular LymphomaPHASE2 · Recruiting · City of Hope Medical Center · Duarte, California
- Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaPHASE1 · Recruiting · City of Hope Medical Center · Duarte, California